Incyte Genomics Inc - INCY STOCK NEWS

Incyte has been named among the top five biotech and pharma employers by Science magazine for the seventh consecutive year, ranking third in 2024. The company was specifically recognized for its commitment to employee respect, social responsibility, and employee loyalty.

Additionally, Incyte received recognition from Newsweek as one of America's 100 Most Loved Workplaces and Most Loved Global Workplaces. These accolades highlight the company's dedication to fostering innovation, growth, and passion within its workforce. The complete Science magazine Top Employers survey and rankings will be featured in the October 25, 2024 print issue.

Incyte (Nasdaq:INCY) has expanded its Moments of Clarity program, an educational initiative highlighting stories of people living with mild to moderate atopic dermatitis (AD). The program now features additional patient perspectives, including Dr. Sandra Lee (known as Dr. Pimple Popper) and Emily, a mom of three. They share their experiences with AD and finding relief with Opzelura® (ruxolitinib) cream 1.5%.

Opzelura is a nonsteroidal, twice-daily cream for short-term and non-continuous treatment of mild to moderate eczema in certain people 12 and older. In a pivotal clinical trial, 54% of patients had clear to almost clear skin at 8 weeks, and 52% had a significant reduction in itch. The program aims to empower others to seek appropriate treatment and raise awareness about AD, which affects over 21 million people aged 12 and older in the U.S.

Incyte (Nasdaq:INCY) has announced the schedule for its third quarter financial results conference call and webcast. The event is set for October 29, 2024, with the following timeline:

• Q3 2024 Press Release: 7:00 a.m. ET
• Q3 2024 Conference Call: 8:00 a.m. ET

Participants can join via phone using the provided domestic and international dial-in numbers, or access the live webcast with slides at Investor.Incyte.com. A replay of the call will be available for thirty days, and the webcast will be accessible for ninety days.

Incyte (Nasdaq:INCY) has announced the granting of restricted stock unit awards (RSUs) to 26 new employees, representing a total of 22,107 shares of the company's common stock. These awards were made under Incyte's 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of October 1, 2024. The grants were approved by the compensation committee of Incyte's board of directors as an inducement for new employees joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the vesting commencement date, contingent on the employee's continued service with Incyte.

Incyte (Nasdaq:INCY) has announced an equity inducement award granted to Lee Heeson, the company's new Executive Vice President, Incyte International. The award, approved by the compensation committee of Incyte's Board of Directors, is in accordance with Nasdaq Listing Rule 5635(c)(4).

Mr. Heeson received 26,447 restricted stock units (RSUs) with a grant and vesting commencement date of October 1, 2024. The RSUs will vest in four equal installments of 25% each on the first four anniversaries of the vesting commencement date, contingent upon Mr. Heeson's continued service with Incyte on each vesting date.

Incyte (Nasdaq:INCY) announced that key data from its dermatology portfolio, including five late-breaking oral presentations, will be presented at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam. The presentations focus on expanding treatment options for immune-mediated dermatologic conditions such as vitiligo, atopic dermatitis, hidradenitis suppurativa, and prurigo nodularis.

The data highlights Incyte's efforts to evaluate the efficacy and safety of ruxolitinib cream in new patient populations and deepen understanding of povorcitinib in immune-mediated dermatologic conditions. Key presentations include studies on ruxolitinib cream for vitiligo, atopic dermatitis in children, hidradenitis suppurativa, and cutaneous lichen planus. Additionally, a study on oral povorcitinib for prurigo nodularis will be presented.

Several ePosters will also be presented, focusing on the efficacy and safety of ruxolitinib cream and povorcitinib in vitiligo treatment.

Incyte and Syndax Pharmaceuticals announced the publication of pivotal Phase 2 AGAVE-201 trial results for Niktimvo™ (axatilimab-csfr) in The New England Journal of Medicine. The trial met its primary endpoint across all dose cohorts, with 74% of patients achieving a complete or partial response within the first six months of treatment at the 0.3 mg/kg every 2 weeks dose. Niktimvo has been approved by the U.S. FDA for treating chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. It has also been added to the latest NCCN Guidelines® for chronic GVHD treatment. The drug showed rapid, durable responses in all organs studied and patient subgroups, with 60% of patients reporting clinically meaningful symptom burden reduction.

Incyte (INCY) announced promising early clinical data for INCB123667, a highly selective CDK2 inhibitor, in patients with advanced solid tumors. The trial results, presented at ESMO 2024 and during Incyte's investor event, show potential for treating cancers with increased Cyclin E1 activity. Key findings include:

- In platinum-resistant ovarian cancer patients (n=37), a 24.3% overall response rate was observed across three dose levels.

- The highest response rate of 31.3% was found in the 50mg BID cohort.

- A disease control rate of 75.7% was achieved in ovarian cancer patients.

- INCB123667 demonstrated a manageable safety profile with common adverse events including thrombocytopenia, anemia, and neutropenia.

Incyte plans to initiate a pivotal study in ovarian cancer in 2025 and explore combination treatments.

Incyte (Nasdaq:INCY) announced positive results from the Phase 3 POD1UM-303/InterAACT2 trial of retifanlimab (Zynyz®) in combination with platinum-based chemotherapy for treating adults with inoperable locally recurrent or metastatic squamous cell anal carcinoma (SCAC). The trial met its primary endpoint, demonstrating a 37% reduction in the risk of progression or death. Key findings include:

- Median progression-free survival: 9.3 months (retifanlimab) vs 7.4 months (placebo)
- Median overall survival: 29.2 months vs 23 months
- Overall response rate: 56% vs 44%
- Duration of response: 14 months vs 7 months

Incyte plans to file a supplemental Biologics License Application (sBLA) for retifanlimab in SCAC by year-end 2024.